Ornithine Transcarbamylase Deficiency Clinical Trials 2023

Ornithine Transcarbamylase Deficiency Clinical Trials 2023

Ornithine Transcarbamylase Deficiency research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in ornithine transcarbamylase deficiency clinical trials today.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to ornithine transcarbamylase deficiency

What are the top hospitals conducting ornithine transcarbamylase deficiency research?

When it comes to advancing research and finding innovative treatments for ornithine transcarbamylase deficiency (OTC deficiency), several top hospitals are leading the charge. In Salt Lake City, the University of Utah has taken proactive steps in addressing this rare genetic disorder with two active clinical trials dedicated to OTC deficiency. Although relatively new to this area of study, having recorded their first trial in 2020, they have already made significant strides towards improving outcomes for patients. Similarly, at the University of Colorado in Aurora, researchers are conducting one ongoing trial focused on OTC deficiency. Despite their recent entry into this field with a trial initiated in 2022, they demonstrate a strong commitment to making advancements.

Located in Chicago, Ann & Robert H. Lurie Children's Hospital is also engaged in tackling OTC deficiency through an active clinical trial. Their dedication reflects the urgency and importance of finding effective solutions for individuals living with this condition as they too embarked on their first investigation related to OTC deficiency in 2022.

Meanwhile, at University Hospitals Cleveland Medical Center in Ohio, renowned medical professionals have been actively working on understanding and treating OTC deficiency since 2012 when they commenced their initial trial. With one ongoing investigation currently underway and two completed studies under their belt thus far, they continue striving towards improved patient outcomes.

Notably contributing from across the border is The Hospital for Sick Children located within Toronto's vibrant healthcare landscape. They too are delving into research regarding OTC deficiency through an ongoing clinical trial initiated just last year (in 2022); demonstrating a shared commitment among these institutions toward unraveling mysteries surrounding this rare metabolic disorder.

Although each hospital mentioned above may be engaged differently based on location or prior experiences within ornithine transcarbamylase deficiency trials overall; together these esteemed establishments represent hope for those living with or affected by this complex condition while showcasing unwavering determination among global medical community pushing boundaries to find solutions and improve the lives of individuals affected by OTC deficiency.

Which are the best cities for ornithine transcarbamylase deficiency clinical trials?

When it comes to ornithine transcarbamylase deficiency clinical trials, several cities stand out as leaders in research and development. Salt Lake City, Utah takes the lead with 2 active trials focused on studying treatments such as DTX301 and ARCT-810. Aurora, Colorado follows closely with 1 ongoing study examining DTX301. Additionally, Chicago, Illinois; Cleveland, Ohio; and Toronto, Ontario each have 1 active trial investigating potential treatments for this condition. These cities offer individuals affected by ornithine transcarbamylase deficiency access to cutting-edge clinical trials that aim to advance knowledge of this rare genetic disorder and explore new therapeutic options.

Which are the top treatments for ornithine transcarbamylase deficiency being explored in clinical trials?

Promising treatments for ornithine transcarbamylase deficiency (OTCD) are making strides in clinical trials. DTX301, a groundbreaking therapy, is currently being tested in one active trial dedicated to OTCD. This innovative treatment option made its debut on the scene in 2022 and has already shown immense potential. Another contender gaining attention is ARCT-810, with one ongoing trial specifically targeting OTCD patients. Since its introduction in 2020, it has participated in three clinical trials focused on addressing this rare genetic disorder. These advancements offer hope for individuals affected by OTCD and bring us closer to effective treatment options for this challenging condition.

What are the most recent clinical trials for ornithine transcarbamylase deficiency?

Recent clinical trials have offered hope for individuals living with ornithine transcarbamylase deficiency (OTC). One of the most promising developments is DTX301, a treatment currently in Phase 3 trials. This therapy shows potential in addressing the underlying cause of OTC by delivering functional copies of the OTC gene to patients. Another trial, ARCT-810, has entered Phase 1 and aims to develop RNA-based therapies as a potential treatment option for OTC. These advancements bring optimism to those affected by this rare genetic disorder, offering new possibilities for improved quality of life and disease management.

What ornithine transcarbamylase deficiency clinical trials were recently completed?

Recently, there have been significant advancements in clinical trials targeting ornithine transcarbamylase deficiency (OTCD), a rare metabolic disorder. Notably, a trial sponsored by the National Institutes of Health (NIH) was completed recently with promising results. The study investigated the effectiveness of a new therapy specifically designed for OTCD patients and highlighted potential improvements in managing this condition. These positive outcomes provide hope for individuals affected by OTCD and demonstrate ongoing efforts to advance treatment options for this challenging disorder.